AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03009877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl will be administered at the beginning of induction, 2 micrograms per kilogram.
Study NCT03009877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: midazolam will be given upon induction, 1-2 milligrams at the anesthesiologist's discretion.
Study NCT01084200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol for maintenance
Description: Propofol 6-8mg/kg/h + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
Study NCT01084200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane 0.7-1.3MAC + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
Study NCT01084200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane+Propofol
Description: Sevoflurane 0.7-1.3MAC + Remifentanil 0.1-0.2ug/kg/min + Propofol 2mg/kg/h for anesthesia maintenance
Study NCT01292694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Oral, single-dose, 50 mg tablet
Study NCT01292694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril
Description: Oral, single-dose, 50 mg tablet
Study NCT01292694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, single administration, gelatin capsule filled with microcrystalline cellulose
Study NCT02347215 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life assessment
Description: Seattle Angina Questionnaire and other questionnaires.
Study NCT02347215 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stress imaging
Description: Stress imaging
Study NCT01579045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: bilateral daily use soft contact lens
Study NCT02762838 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-055
Description: BCD-055 is infliximab biosimilar
Study NCT02762838 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Remicade®
Study NCT01579045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: bilateral daily use soft contact lens
Study NCT01579045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nelfilcon A
Description: bilateral daily use soft contact lens
Study NCT01579045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filcon II 3
Description: bilateral daily use soft contact lens
Study NCT01579045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filcon II 3
Description: bilateral daily use soft contact lenses
Study NCT04623879 — intervention group
Intervention type: DRUG
Intervention: Lumacaftor, Ivacaftor Drug Combination
Study NCT02511054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Description: Chloroquine Phosphate is a 4-aminoquinoline compound that is commercially available for oral administration. It is a white, odorless, bitter tasting, crystalline substance freely soluble in water; and widely used for the treatment andprophylaxis of malaria. It is supplied and manufactured in tablets of 500 mg (equivalent to 300 mg chloroquine phosphaste base)
Study NCT02511054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine (PYR)
Description: PYR is a folic acid antagonist that is commercially available; and has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide. It is manufactured in tablets of 25 mg.
Study NCT02511054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sanaria PfSPZ Challenge (NF54)
Description: Sanaria PfSPZ Challenge are aseptic, cryopreserved P.falciparum sporozoites used for CHMI trials, produced by the biotechnology company; Sanaria Inc. In brief, manufacture includes the production, under traditional environmental conditions, of eggs from a colony of A. stephensi mosquitoes housed in a controlled environmental chamber. The sporozoites are purified, counted, and, at a specified concentration, cryopreserved. Cryopreservation commences with the addition of cryoprotective additives to the purified sporozoites to produce the Sanaria PfSPZ Challenge product. Sanaria PfSPZ Challenge is dispensed into screw-cap vials containing 15,000, 50,000, or 100,000 PfSPZ in a 20 L aliquot. Sanaria PfSPZ Challenge is stored in liquid nitrogen vapour phase at 140 (Infinite)C to -196 (Infinite)C.
Study NCT01037595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turmeric
Description: turmeric 500 md tid orally for 8 weeks
Study NCT01037595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 3 time orally for 8 weeks
Study NCT01037595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turmeric
Description: 500 mg tid orally for 8 weeks
Study NCT03141229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction
Study NCT03141229 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness based stress reduction
Study NCT02064322 — intervention group
Intervention type: DEVICE
Intervention: SImmetry Implant
Description: The SImmetry system is commercially available. The implanted devices consist of a range of thread-tapping cannulated implants designed to transfix the sacrum and ilim, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion.
Study NCT01662921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH
Description: Long acting insulin NPH dosing will be titrated weekly derived from the patients current weight and gestational age
Study NCT01662921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin LISPRO
Description: Insulin lispro dosing will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
Study NCT01662921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine
Description: Insulin glulisine will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
Study NCT02764801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound contrast agent (Contrast-enhanced ultrasound)
Description: Intravenous injection of ultrasound contrast agent followed by saline flush though an angiocatheter in the arm or hand.
Study NCT02764801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Logiq E9 Scanner (Contrast-enhanced ultrasound)
Description: Ultrasound scanning using a commercial scanner with a C1-5-D broad-spectrum convex transducer followed by a RAB2-5-D broad-spectrum real-time 4D transducer.
Study NCT02762838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: All patients will receive methotrexate in a dose from 10 to 25 mg per week.
Study NCT02762838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: All patients will receive methotrexate in a dose from 10 to 25 mg per week.
Study NCT02543372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Couples Therapy (BCT)
Description: BCT integrates cognitive behavioral techniques targeting problem gambling with a large focus on interventions for relationship functioning. The BCT condition requires active participation from both the gambler and the CSO.
Study NCT02543372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The CBT integrates cognitive behavioral techniques targeting problem gambling with some interventions for relationship functioning.The CBT condition requires active participation from the gambler, but not for the CSO.
Study NCT04483492 — intervention group
Intervention type: DRUG
Intervention: Caffeine citrate
Description: diaphragm contractility after administration
Study NCT03403751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reltecimod 0.5 mg/kg
Description: Single IV infusion of 0.5 mg/kg Reltecimod (at a concentration of 1 mg/mL) over approximately 10 minutes
Study NCT03403751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV infusion of 0.5 mL/kg of 0.9% saline (volume equivalent to Reltecimod dosing schema) over approximately 10 minutes
Study NCT03944759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: serratus anterior plan block
Description: serratus anterior plan block
Study NCT02103959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX-2043
Description: Slow bolus IV administration of CMX-2043
Study NCT02103959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Slow bolus IV administration of PBS
Study NCT02140216 — intervention group
Intervention type: BIOLOGICAL
Intervention: No blood transfusion
Description: No blood transfusion
Study NCT02140216 — intervention group
Intervention type: BIOLOGICAL
Intervention: Day 0 blood transfusion
Description: Patients undergoing elective spine surgery receiving intra- or immediate-postoperative red cell blood transfusion.
Study NCT02140216 — intervention group
Intervention type: BIOLOGICAL
Intervention: Day 1 or 2 blood transfusion
Description: Patients undergoing elective spine surgery receiving first red cell blood transfusion on day 1 or 2 after surgery.
Study NCT00455559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Study NCT00455559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Study NCT03505593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENVUE System
Description: The ENvizion Medical™ ENVUE™ System is designed to aid qualified operators in the placement of the ENvizion Medical™ Enteral Feeding Tube™ into the stomach or small intestine.
Study NCT03796416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: used at a rate of 25 mcg Q4hours for cervical ripening.
Study NCT03796416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: used at a rate of 25 mcg Q4hours for cervical ripening.
Study NCT02517242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pens Device
Study NCT02517242 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Syringe
Study NCT02517242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring capillary blood glucose with blood glucose monitor, lancet tapes and capillary blood glucose tests (3 tests/day)
Study NCT02517242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring capillary blood glucose with blood glucose monitor, lancet tapes and capillary blood glucose tests (3 tests/day)
Study NCT03004170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training
Study NCT03004170 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-Administered Coping Effectiveness Training
Study NCT03188068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Oral administration
Study NCT03188068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral administered with sirolimus
Study NCT01077739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil (5FU)
Description: standard FOLFOX regimen
Study NCT01077739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: standard FOLFOX regimen
Study NCT01077739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5 mg/kg iv infusion every 3 weeks OR 5 mg/kg iv infusion every 2 weeks
Study NCT01077739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: standard XELOX regimen
Study NCT01077739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: standard XELOX or FOLFOX regimen
Study NCT04203992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Videogame
Description: True Champion is an educational, values-based game that aims to empower young athletes to make informed decisions to avoid doping.~Participants engaging in the videogame sessions will encounter a series of thought-provoking situations and knowledge tests. Players will help their assigned character navigate through these curriculum-rich scenarios in order to reach their performance goals in a healthy and ethical way.
Study NCT02762838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: All patients will receive folic acid in a dose of 5 mg per week.
Study NCT02762838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: All patients will receive folic acid in a dose of 5 mg per week.
Study NCT00152971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Dose 1 - day 2 to completion
Description: low dose regimen taken once daily
Study NCT00152971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Dose 1 - day 1
Description: low dose regimen taken once daily
Study NCT00152971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Dose 2 - day 2 to completion
Description: high dose regimen taken once daily
Study NCT00152971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Dose 2 - day 1
Description: high dose regimen taken once daily
Study NCT00152971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 30 mg subcutaneously twice daily
Study NCT03820323 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: POC VL and targeted DRM testing.
Description: Point-of-care Viral Load Testing will be done to ensure that providers and caregivers receive the results with in 24 hours study. Targeted DRM testing will be performed during the initiation of ART and when viremia (VL>1000 copies/mL) is detected.
Study NCT03820323 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SOC VL testing
Description: SOC VL testing is done at 6 months after ART initiation then every 3 months if unsuppressed, otherwise every 12 months. DRM testing is conducted only if failing 2nd line ART.
Study NCT01058434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Study NCT03395834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O3
Description: O3 TM and INVOS® monitoring simultaneously in single patient during 3 min of vascular occlusion test
Study NCT02576158 — intervention group
Intervention type: PROCEDURE
Intervention: TCT，HPV，colposcopic inspection
Study NCT03191929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIT Intervention
Description: Patients in the HIT intervention completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider. Patients' scores were transmitted to the provider prior to their clinic visit.~Providers in the HIT intervention received a web-based training developed by the Harvard Program in Refugee Trauma to train providers in delivering culturally competent, trauma-informed care to address mental health problems and other trauma-related medical issues in patients who experienced extreme war trauma. Providers also received ongoing clinical decision support through a mobile application to support the diagnosis and initiation of treatment for depression and/or PTSD.
Study NCT03191929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Intervention Control Arm
Description: Patients in the Minimal Intervention Control Arm completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider; however, patients' scores in the Minimal Intervention Control Arm were only transmitted to the provider prior to their clinic visit if they showed evidence of being at risk to harm either themselves or others.~Providers in the Minimal Intervention Control Arm completed the online tutorial, A physician's practical guide to culturally competent care, which was provided by The Office of Minority Health, US Department of Health and Human Services Website.
Study NCT05983744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0 Hz Control
Description: Lower body negative pressure (LBNP) applied to -60 mmHg for 10-min
Study NCT05983744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.1 Hz PPT
Description: Lower body negative pressure (LBNP) applied at a frequency of 0.1 Hz from -30 mmHg to -90 mmHg
Study NCT05983744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.05 Hz PPT
Description: Lower body negative pressure (LBNP) applied at a frequency of 0.05 Hz from -30 mmHg to -90 mmHg
Study NCT00545363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Participants will receive ibandronate 150 mg QM orally for 6 months.
Study NCT00545363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate
Description: Participants will receive ibandronate 150 mg QM orally for 6 months.
Study NCT02001974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel+Reparixin
Description: Association of Paclitaxel at fixed dosage with three increasing dosage of Reparixin
Study NCT00747526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium 5 mg
Description: Type= exact number, unit= mg, number= 5, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to Day 5; possible extension using 5 mg once daily up to 28 consecutive days.
Study NCT00747526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium 10 mg
Description: Type= exact number, unit= mg, number= 10, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to up to Day 14; possible extension using 10 mg once daily up to 28 consecutive days.
Study NCT02153359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Efficiency Particulate Air Cleaner
Study NCT02153359 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High Efficiency Particulate Air Cleaner
Study NCT02153359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham air cleaner
Study NCT02153359 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham air cleaner
Study NCT03377868 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Optic coherence tomography
Description: Optic coherence tomography measures retinal layer thickness, macular volume , and cell inner plexiform layer.
Study NCT03377868 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pulmonary function test
Description: Pulmonary function test measures forced vital capacity and forced expiratory volume in one second.
Study NCT03655990 — intervention group
Intervention type: DEVICE
Intervention: Treatment with the JUVORA™ Dental Disc
Description: treatment with the JUVORA™ Dental Disc
Study NCT01099930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT),
Description: Stem Cell Mobilization with Cyclophosphamide 4.5 gm/m2 and rhGCSF 10 ug/kg/d x 10 day.~Stem Cell Collection with Cobe Spectra Stem Cell Purification with Miltenyi CliniMACS Stem Cell Transplant Conditioning with Busulphan 9.6 mg/kg iv, Cyclophosphamide 200 mg/kg iv, rabbit ATG 5 mg/kg iv followed by CD34 selected autologous hematopoietic stem cell transplant
Study NCT01099930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Patient will receive standard therapy as decided upon by their treating neurologist.
Study NCT02707523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 10 mg
Study NCT02707523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 20mg
Study NCT02707523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04610762 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GeneXpert HCV VL Fingerstick test
Description: The participants will have a molecular test (GeneXpert HCV VL Fingerstick, Cepheid) that quantifies hepatitis C virus (HCV) RNA levels directly from a fingerstick blood sample.
Study NCT04246515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Training
Description: Vascular occlusion of the injured limb.
Study NCT04203992 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will be given an anti-doping booklet prepared by UNESCO. This booklet is considered standard educational material, i.e. what might be presented to young athletes as part of their regular sports curriculum.
Study NCT04246515 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Blood Flow Restriction Training
Description: Blood Flow Restriction material will be attached to the limb without vascular occlusion.
Study NCT04246515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic rehabilitation
Description: Classic rehabilitation protocol after a hamstring injury consisiting out of stretching, strength, core stability,...
Study NCT00579982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Experimental formulation